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Abstract
Introduction—Three common haplotypes in the gene encoding catechol-O-methyltransferase
(COMT) have been associated with pain modulation and the risk of developing chronic
musculoskeletal pain, namely temporomandibular disorder (TMD). Haplotypes coding for higher
enzymatic activity were correlated with lower pain perception. Rodent studies showed that COMT
inhibition increases pain sensitivity via β2/3-adrenergic receptors. We hypothesized that the non-
selective β-adrenergic antagonist propranolol will reduce clinical and experimental pain in TMD
patients in a manner dependent on the subjects’ COMT diplotype.
Methods—40 female Caucasian participants meeting the Research Diagnostic Criteria for TMD
were genotyped for COMT polymorphisms and completed a randomized, double–blind, placebo-
controlled, two-period crossover pilot study. Each period consisted of a baseline assessment week
followed by an intervention week (propranolol or placebo). Changes in clinical pain ratings,
psychological status, and responses to heat and pressure stimuli between baseline and intervention
weeks were compared across periods.
Results—The number of patients reporting a reduction in pain intensity rating was greater during
propranolol treatment (p=0.014) compared with placebo. Propranolol significantly reduced a
composite pain index (p=0.02) but did not decrease other clinical and experimental pain ratings.
When stratified by the COMT high activity haplotype, a beneficial effect of propranolol on pain
perception was noted in subjects not carrying this haplotype, a diminished benefit was observed in
the heterozygotes, and no benefit was noted in the homozygotes.
Conclusion—COMT haplotypes may serve as genetic predictors of propranolol treatment outcome,
identifying a subgroup of TMD patients who will benefit from propranolol therapy.
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Introduction
Amongst the various chronic musculoskeletal pain conditions, temporomandibular disorder
(TMD) is the most common. It is characterized by persistent pain in the masticatory and related
muscles of the head and neck, pain in the temporomandibular joint(s) (TMJ), and limitation in
jaw functions [1]. The prevalence of TMD ranges from 6% to 12 % in the general population
[2-4]. Numerous epidemiological studies indicate a female preponderance [5], and women
constitute up to 80% of the patients seeking treatment for TMD [6].
Consistent with a general state of pain amplification, TMD patients often complain of persistent
pain in multiple body sites beyond the affected orofacial region [7,8]. Compared to pain-free
subjects, TMD patients reported greater sensitivity to noxious stimuli applied to remote body
sites [9-12]. Between 20% to 80% of TMD patients reportedly suffer from a variety of other
chronic pain disorders such as headache, low back pain, fibromyalgia, and irritable bowel
syndrome [13-19]. Furthermore, elevated psychological distress, somatic body awareness,
depression, and anxiety disorder are notable comorbidities [20-24]. Taken together, these
findings suggest that TMD is a chronic pain disorder characterized by dysfunction of the
nociceptive system resulting from a complex interplay of biological, psychological, and social
factors [5].
Studies have provided substantial evidence that pain perception, and the susceptibility to
chronic persistent pain conditions, are partly mediated by genetic factors [25]. Recent studies
have identified several candidate genes associated with pain sensitivity, susceptibility to
chronic pain disorders, and response to pain therapies [26]. The catechol-O-methyltransferase
(COMT) gene which codes for an enzyme that metabolizes catecholamines (namely
epinephrine, norepinephrine, and dopamine) is one such gene implicated in the regulation of
pain perception. TMD patients exhibit lower COMT activity than pain-free controls [27]. The
COMT gene contains multiple single-nucleotide polymorphisms (SNPs). However, a
nonsynonymous amino acid exchange has been described only for SNP rs4680 (also called
Val(108/158)Met), which codes for a valine-to-methionine substitution. This substitution
reduces the activity of COMT enzyme by approximately fourfold [28]. The low activity Met
allele is linked with increased sensory and affective ratings of experimentally evoked pain
[29], fibromyalgia [30], migraine [31], and morphine efficacy in cancer pain treatment [32].
However, an association of Val(108/158)Met with various responses to experimental pain
measures was not observed in acute postsurgical pain [33,34].
Current research suggests that haplotype-based association methods are more powerful than
analogous allele-based methods when multiple disease susceptibility variants occur in the same
gene. We recently reported that COMT haplotypes, rather than individual SNPs, better
accounted for the observed variability in pain sensitivity. Three major haplotypes of COMT,
designated as low pain sensitive (LPS), average pain sensitive (APS), and high pain sensitive
(HPS) according to the responses to experimental pain stimuli, accounted for 11% of variability
in experimental pain sensitivity in women and were predictive of the risk of TMD onset [35,
36]. COMT haplotypes were also associated with pain severity in fibromyalgia patients and
subjects with postsurgical shoulder pain [37,38]. The LPS haplotype produces higher levels of
COMT enzymatic activity than the APS or HPS haplotypes [39]. The pharmacological
inhibition of COMT in rats resulted in mechanical and thermal hyperalgesia that was reversed
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by the non-selective β-adrenergic receptor antagonist propranolol, but not by dopaminergic,
α-, or β1-adrenergic antagonists suggesting that the hyperalgesia is mediated by β2/3-adrenergic
mechanism [40]. In fact, a recent study of a single-dose infusion of propranolol to TMD and
fibromyalgia patients revealed a short-term improvement in clinical pain ratings [41].
To investigate the pharmacogenetic effect of COMT on treatment response to propranolol in
chronic persistent pain conditions, we conducted a double-blind, placebo-controlled, two-
period crossover pilot study of propranolol in TMD patients. We hypothesized that one week
of treatment with propranolol (20 mg twice a day) would reduce clinical pain symptoms and
experimental pain sensitivity in TMD patients significantly more than placebo. We further
hypothesized that individuals with COMT haplotypes coding for reduced enzyme activity




This study was approved by the Institutional Review Board at the University of North Carolina
(UNC) at Chapel Hill. Informed consent was obtained from all subjects. Participants were
recruited from patients who sought treatment at the Orofacial Pain Clinic, UNC at Chapel Hill
School of Dentistry, and through advertisements.
Inclusion and Exclusion Criteria
Individuals were eligible for the study if they were between 18 and 60 years of age and met
Research Diagnostic Criteria for TMD (RDC/TMD) [1], Only women were recruited as they
constitute up to 80% of patients seeking treatment for TMD [6]. Only Caucasian patients were
evaluated, due to the necessity of avoiding genetic population stratification bias [42] and the
fact that Caucasians represent the majority of local referral patients.
Exclusion criteria were self-reported asthma, cardiac arrhythmia, coronary artery disease, renal
failure or dialysis, diabetes mellitus, hyperthyroidism, major depression or other major
psychiatric disorders, seizures, drug or alcohol abuse, current chemotherapy or radiation
therapy, pregnancy or nursing, facial trauma or orofacial surgery within the last 6 weeks, and
orthodontic treatment. To minimize the risk of an adverse hypotensive response to β-blockade,
subjects with heart rate (HR) under 55 bpm and diastolic blood pressure below 50 mmHg were
excluded from the study. Patients taking the following medications were also excluded: drugs
with central nervous system activity (e.g., opioids, benzodiazepines, nonbenzodiazepine
sedative hypnotics, tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs),
and anticonvulsants) and β-blockers. The use of selective serotonin reuptake inhibitors (SSRIs)
was permitted only if the subject had already been taking it for at least 1 month before study
enrollment. Abortive medications for headaches (such as the triptans) and nonsteroidal anti-
inflammatory drugs (NSAIDs) were not allowed during the last 2 days prior to the study visits.
Study design
This study was a randomized, double–blind, placebo-controlled, two-period crossover clinical
trial. The Investigational Drug Service at the UNC Hospitals performed the randomization,
and kept the master list of assignments. The treatment sequence code for each subject was not
disclosed to the project investigators till completion of the entire research protocol. Following
a 1-week baseline assessment period, patients were randomly allocated in blocks of 8 to
commence in one of two study arms. The first arm started with 1week of active treatment,
followed by a 1-week wash-out period, and then a 1-week placebo period. The second arm
started with 1-week of placebo, followed by a 1-week wash-out period, and then a week of
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active treatment. During the active treatment period subjects received 20 mg of propranolol
twice a day. Placebo pills were identical to the propranolol pills to ensure subject and
investigator blinding. To monitor compliance, subjects returned all unused pills at the next
study visit.
At initial screening, a RDC/TMD examination and electrocardiogram (ECG) was performed,
medical history was recorded, and subjects completed a battery of psychological questionnaires
(described below). At every subsequent study visit, the following were administered: 1) Pain
self-report (PSR), 2) quantitative sensory testing (QST), 3) psychological questionnaires, and
4) cardiovascular system (CVS) measures.
Outcome measures
Pain self-report (PSR)—Pain intensity rating was obtained via the PSR based on a ‘0’ to
‘100’ numerical rating scale (NRS), whereby ‘0’ is ‘no pain at all’ and ‘100’ is ‘the most intense
pain imaginable’. Subjects rated their lowest, average, and highest pain level for the past week.
The average weekly pain intensity was the primary outcome variable for this study. Pain
duration was determined by asking participants to denote the percentage of time during the
waking day when they experienced pain. A pain index was calculated as a product of pain
intensity by pain duration. Pain duration and pain index were considered as secondary outcome
measures.
Quantitative sensory testing (QST)
Heat pain threshold and tolerance: Contact heat stimuli were delivered using a computer-
controlled Medoc Thermal Sensory Analyzer (TSA-II, Ramat Yishai, Israel), a Peltier-
element-based stimulator with a 15-15 mm surface area. Thermal threshold and tolerance were
measured on the left ventral forearm by an ascending method of limits. Thermal pain threshold
was defined as the temperature (°C) at which the subject first perceived heat pain, whereas
thermal pain tolerance was defined as the temperature (°C) at which the subject could no longer
tolerate the pain. The temperature increased from a baseline of 32°C with a 0.5°C/s rate of rise
until the subject responded by pressing the button. The cutoff temperature for both
measurements was 50°C. Average thermal threshold and tolerance values was calculated from
4 trials conducted with a 30-s inter-stimuli interval at different sites of the ventral forearm.
Pressure pain threshold (PPT): The PPT was assessed over the right and left temporalis and
masseter muscles, and the TMJs with a pressure algometer (Pain Diagnosis and Treatment,
Great Neck, NY, USA). The PPT was defined as the amount of pressure (kg) at which the
subject first perceived the stimulus to be painful. One pre-trial assessment was performed at
each site followed by additional assessments until two consecutive measures differing by less
than 0.2 kg were obtained. The maximum number of assessment at each site was 5. Pressure
stimuli were delivered at an approximate rate of 1 kg/s. The cutoff pressure for all sites was 5
kg. The values from the right and left sides were averaged to obtain one PPT value per
anatomical site. The heat pain threshold and tolerance and PPT values were secondary
outcomes for this study.
Psychological questionnaires—The Beck Depression Inventory (BDI-II) is a 21-item
self-report rating questionnaire that assesses depressive symptoms [43]. The State-Trait
Anxiety Inventory (STAI) contains two 20-item instruments, one of which evaluates situational
state anxiety (Form Y-1) and the other assesses trait anxiety (Form Y-2) [44]. The Perceived
Stress Scale (PSS) assesses 10 sources of stress and produces an overall perceived stress rating
[45]. Higher scores indicate greater level of psychological dysfunction in each of these
questionnaires. All of them are validated and widely used in clinical pain studies.
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Cardiovascular system (CVS) measures—The CVS measures included the systolic
blood pressure (SBP), the diastolic blood pressure (DBP), and the heart rate (HR)
measurements. They were assessed on the right arm using the Dinamap 1846 automatic vital
signs monitor (Critikon, Inc., Tampa, FL, USA). Following a 15-minute seated rest period, 3
readings for each CVS measure recorded at 2-minute intervals were obtained. The averaged
resting SBP, DBP, and HR were secondary outcomes for this study.
Genotyping
This study was nested within a larger study designed to assess the biopsychosocial and genetic
risk factors that contribute to the onset and persistence of TMD and related conditions. Genomic
DNA was purified from whole blood samples by Cogenics Inc. (Morrisville, NC, USA) using
the Gentra Puregene DNA Isolation Kit™ (Qiagen, Valencia, CA, USA) and genotyped on the
Affymetrix CogPain GeneChip™ which contains 3,295 SNPs located within 358 loci of genes
implicated in pain transmission and modulation. Samples and SNPs were subsequently
subjected to a 95% call rate threshold and 99% filter for repeatability. SNPs which deviated
from the Hardy-Weinberg equilibrium were identified and removed from the analysis.
Genotyping data for the COMT gene alone was retrieved for this study.
Previous reports showed that 4 SNPs, namely rs6269, rs4633, rs4818, and rs4680 (SNPs
number cited from NCBI databases) (Fig. 1), determined the 3 major COMT haplotypes that
were associated with individual differences in a global pain measure as well as thermal pain
sensitivity in healthy women [35,36]. These 3 haplotypes were designated as LPS for GCGG,
APS for ATCA, and HPS for ACCG allelic composition. To reconstruct these haplotypes,
genotyping data was retrieved for the above mentioned SNPs. PLINK, version 1.06, software
program was used for reconstructing the haplotypes from unphased genotype data [46]
(http://pngu.mgh.harvard.edu/purcell/plink/).
Statistical analysis
We estimated that with recruitment of 40 subjects, this pilot study would provide 80% power
to detect a difference of 8 points between propranolol and placebo periods in the primary
outcome variable, change in PSR pain intensity rating. A difference of 8 NRS points is
equivalent to a 30% post-treatment reduction in PSR pain intensity rating for the propranolol
period compared to a 5% reduction for the placebo period. The study also had 80% power to
detect a difference among three COMT diplotypes of 25 NRS points in the net change in PSR
pain intensity rating described below (i.e., within-subject difference between placebo and
propranolol periods in change scores). The calculations were made using SAS PROC POWER
for within each subject effects, specifying a two tailed, type I error of p=0.05 and assuming
the observed standard deviation in net change of 16.8.
For each of the 14 outcome variables, within-subject change scores during each treatment
period were computed by subtracting the value at the start of the treatment period from the
value at the end of the treatment period. The within-subject, net outcome score was used to
examine the relationship between propranolol efficacy and the number of LPS alleles. This
measure of net change was calculated by subtracting the individual's change over the placebo
period from the change over the propranolol period.
The PSR pain intensity rating was chosen a priori as the primary outcome variable, and thus
the Type I error was controlled at the 2-sided 0.05 level for this variable. For the primary
outcome variable, no adjustments were made for multiple comparisons because there was only
one such variable. A multiplicity adjustment was not performed for the secondary measures
because they were viewed as exploratory measures, and it was not the intent of the study to
assess these secondary measures at the same experimental significance level as was established
Tchivileva et al. Page 5













for the primary variable. Each outcome variable was tested for normality of its distribution
using the Kolmogorov-Smirnov test and for homogeneity of variance by Levene's test.
Psychological scores failed the test for normal distribution, so they were compared with
Wilcoxon signed rank test or Kruskal-Wallis test. Other outcome variables, including the
primary outcome, did not violate the diagnostic tests, and were evaluated with parametric tests.
A General Linear Model (GLM) procedure was used for repeated-measures analyses of the
mean ratings from weekly PSR, experimental pain measurements, and CVS measures. In the
GLM model, the treatment (propranolol or placebo) was the independent variable, and the only
covariate was the study sequence, which was included to analyze paired data. A possible
carryover effect was assessed by independent t-test, and no statistically significant carryover
effect was observed for any study outcome (data not shown). Statistical evaluation of variation
in the net outcome changes among the number of COMT LPS haplotype alleles was performed
by one-way analysis of variance (ANOVA) with Tukey's post hoc test. Yates’ correction was
implemented for Chi-square analysis of categorical data. Statistical analyses were done using
SPSS software, version 16 (SPSS INC., Chicago, IL, USA).
The data derived from the study were analyzed using an intent-to-treat analysis. The intent-to-
treat population included those subjects who, once randomized, had evidence of taking at least
one dose of the study medication and attended at least one subsequent evaluation.
Results
Study population
Of the 93 subjects screened, 42 subjects were eligible for this study (Fig. 2). One subject was
excluded at the first visit because her DBP was lower than 50 mmHg, and another subject
dropped-out of the study after the first baseline assessment citing time constrains. Therefore,
40 subjects successfully completed this study. Medication adherence estimate (propranolol and
placebo) based on pill return was at 96.4 %. Subjects’ characteristics at baseline are presented
in Table 1. When stratified by the number of COMT LPS alleles, no statistically significant
difference between 3 subgroups was observed in any characteristic. Frequency of COMT
diplotypes in the cohort is presented in Table 2.
Efficacy of propranolol treatment
Clinical pain perception—A significantly greater percentage of patients (67.5% vs. 32.5%)
experienced reduction in PSR pain intensity rating during the propranolol treatment period
than the placebo treatment period (chi square = 8.450, p = 0.014). However, reduction in PSR
pain intensity rating comparing propranolol treatment to placebo treatment did not reach the
statistical significance (Wilks’ lambda = 0.932, p = 0.104) (Table 3). Reduction in pain duration
was also nonsignificant, while the change in pain index was statistically significant (Wilks’
lambda = 0.866, p = 0.02) (Table 3).
Experimental pain perception—No significant treatment effect of propranolol on
experimental pain perception (thermal or pressure) was observed. However, the change in
thermal pain tolerance measure compared between treatment periods was close to the threshold
for statistical significance (Wilks'lambda = 0.922, p = 0.081) (Table 3).
Psychological and CVS measures—There were no statistically significant differences
between propranolol and placebo periods in any measure of psychological distress (Table 3).
Among CVS measures, propranolol significantly reduced HR only (Wilks’ lambda = 0.732, p
= 0.001) (Table 3), indicating good patient compliance with the protocol.
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Pharmacogenetic evaluation of propranolol response based on COMT haplotype
Clinical pain perception—A net outcome change was used to evaluate the contribution of
the LPS haplotype number in the effects of propranolol on an individual pain variable. The
number of LPS alleles was associated with statistically significant variation in the net change
in pain index (F(2,37) = 3.836, p =0.031). Association between the number of LPS alleles and
the net change in PSR pain intensity rating approached statistical significance (F(2,37) = 2.626,
p = 0.086) (Fig. 3). Subjects with no LPS alleles (~ 33% of the examined population sample,
Table 2) showed the greatest response. An intermediate effect was observed in the
heterozygotes and no effect was noted in LPS homozygotes (Fig. 3).
Experimental pain perception—The number of LPS alleles was also significantly
associated with the net change in thermal tolerance (F (2,37) = 4.160, p = 0.023), masseter
muscle PPT (F (2,37) = 5.555, p = 0.008), and TMJ PPT (F(2,37)=3.318, p = 0.047) (Fig. 3).
Association between the number of LPS alleles and the net change in temporalis muscle PPT
approached statistical significance (F(2,37) = 2.097, p = 0.137). However, the net change in
thermal threshold demonstrated no association with COMT haplotypes (F(2,37) = 0.182, p =
0.835) (this likely resulted from the higher variability associated with this measure).
Psychological and CVS measures—In contrast to the measures of pain perception, no
association with the number of COMT LPS alleles was found for the net changes in
psychological measures (Table 4), providing evidence that the nature of the effect of
propranolol on pain perception is not neuropsychiatric. A significant association with the
number of COMT LPS alleles was observed for the net HR change (F(2,35) = 4.551, p = 0.017)
but not for the measures of resting arterial blood pressure (Table 4).
Safety
At least one treatment-emergent adverse event was reported by 5 subjects (12.5%) during
propranolol period (namely nausea, diarrhea, insomnia, dizziness, and fatigue) and 4 subjects
(10%) during the placebo period (namely diarrhea, gastrointestinal bloating, fatigue, and
headache). All adverse events were mild and did not result in discontinuation of the study.
Discussion
In this study, we determined that common COMT haplotypes are associated with different
response to β-blocker treatment in a common chronic musculoskeletal pain disorder. This is
the first study that has identified a genetic marker that is associated with the efficacy of
propranolol treatment in patients with TMD. The present findings are consistent with a recent
study that reported that TMD and fibromyalgia patients showed a dysregulation of β-adrenergic
activity which contributed to altered cardiovascular, catecholamine, and clinical pain responses
to psychological and physical stressors. Concordant with our data, acute treatment with
intravenous low-dose propranolol also produced improvement in clinical pain report [41].
The outcome of this proof-of-concept study supports the feasibility and merit of conducting a
larger trial. The trend for improvement in the PSR pain intensity rating and significant
improvement in the pain index supports a likely therapeutic effect of propranolol in a substantial
percentage of TMD patients. It is interesting to note that the pain index , which is a product of
two measures that each yielded smaller estimates of effect and larger p-values in comparing
treatment periods, reached the threshold of statistical significance. This apparent paradox can
be explained by the fact that the individual measures were only moderately correlated
(Pearson's r = 0.5), and it is a tenet of psychometric theory that orthogonal measures that each
are moderately associated with a third variable will yield a stronger association when the two
are combined. While it might be tempting to conclude that the pain index is a statistically
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superior measure of propranolol efficacy, we caution that the result may be idiosyncratic, and
recommend that the index be evaluated in studies with larger samples conducted in other
populations.
While propranolol treatment did not affect measures of sensitivity to experimental pain, a
“dose-response” effect by the number of COMT LPS alleles was observed in the majority of
measures of experimental and clinical pain, with a greater improvement in subjects not carrying
a LPS haplotype, an intermediate effect in the heterozygotes, and no beneficial effect in LPS
homozygotes. The relative benefit for TMD patients without the LPS haplotype identified a
large subgroup (~33% of our sample, Table 2) where β-blocker treatment was advantageous.
In comparison, 20% of the patients showed either no effect or a worsening of their pain
condition in response to propranolol therapy.
The neural mechanisms by which propranolol produces an analgesic effect under conditions
of low COMT activity and high catecholamine bioavailability are poorly understood. However,
both central and peripheral mechanisms have been proposed. In support of a peripheral
mechanism, the intraplantar injection of epinephrine (EPI) produced a peripherally mediated
hyperalgesia in rats, which was blocked by propranolol [47]. Similarly, the intramuscular
injection of low-dose propranolol in rats with carageenan-induced inflammation of the
gastrocnemius muscle reduced inflammatory pain locally [41]. Both propranolol and a
selective β2-adrenoreceptor antagonist reportedly impaired pain behavior in a rodent model of
TMD [48]. Finally, propranolol may produce analgesia by blocking tetrodotoxin-resistant
sodium channels in sensory neurons; however, this is unlikely to contribute to our findings
since relatively high doses are required to observe such effects [49].
The analgesic effect of propranolol may also be mediated via a central mode of action.
Propranolol impairs memory storage and reconsolidation of negative emotional events in
rodents and humans [50-54]. Propranolol is also known to have central nervous system
modulating activities and anxiolytic effects [55,56]. Intraplantar formaline injection in rats
increased extracellular norepinephrine (NE) levels within the ventral part of the bed nucleus
of the stria terminalis (vBNST), brain area which had been implicated in stress responses and
negative affective states, and the injection of the β-adrenergic antagonist timolol into this brain
region dose-dependently attenuated the negative affective component of pain [57].
Catecholamine-induced influence on the autonomic control of the BP may indirectly regulate
pain since increase in BP has been associated with reduced pain sensitivity [58]. In this study,
the chosen dosage of propranolol (20 mg twice a day) was intentionally low to minimize any
reduction in BP which may alter endogenous pain modulation via the baroreceptor reflex,
thereby increasing pain [59,60].
In contrast to the effects of propranolol on pain perception, its effect on anxiety, depression,
and perceived stress were not associated with COMT haplotypes. These results are consistent
with the observation that psychological scores do not vary among various COMT haplotype
groups in healthy female volunteers, and that psychological factors influenced the risk of TMD
onset independent of the COMT haplotypes [61]. A recent open trial of β-adrenergic receptor/
5-HT1A presynaptic autoreceptor antagonist, pindolol, in the fibromyalgia patients reported no
change in the anxiety and depression scores although a significant effect on pain sensitivity
was observed [62]. The lack of change in psychological variables in our study may be partly
explained by the relatively low levels of psychological distress reported by this cohort, the low
dose of propranolol administered, and the lack of effect of propranolol on the psychological
status of TMD patients.
In line with the variable effect of propranolol on pain perception, it is generally recognized
that the pharmacodynamic responses to β-adrenergic receptor blockade are highly inconsistent.
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For example, 30-60% of patients with hypertension who were treated with β-blocker
monotherapy failed to achieve adequate BP control [63,64]. In migraineurs, response rates to
propranolol therapy ranged from 33 to 44% [65]. Variable effects in response to propranolol
treatment have also been reported for anxiety, psychocardiac disorders, aggressive behavior,
and substance withdrawal [56,66-68]. This variability may be accounted for, in part, by
COMT genetic polymorphism.
In this study, a haplotype-based analysis was used instead of a single SNP analysis because
the linkage disequilibrium between several markers showed stronger association with a disease
than individual SNPs, as was observed by Shifman et al. [69]. Consistent with this view, we
previously showed a functional effect of COMT haplotypes on enzyme activity and protein
levels [39]. Nevertheless, in this cohort with only one subject carrying the HPS haplotype, an
association analysis based on Val(108/158)Met polymorphism would lead to a very similar
result compared to a haplotype-based approach.
This study has a few limitations. First, this study was designed as a proof-of-concept trial
recruiting a relatively small number of subjects. Therefore, our findings need to be replicated
in a larger sample set. Second, our results are based on a 1-week low-dose propranolol
treatment. Future studies with a longer duration of treatment and higher dosage levels are
desirable. Third, this study included only Caucasian females because the majority of TMD
patients are women [6]. Hence, the results may not be generalized to men or non-Caucasian
females. Future studies with diverse ethnicity and involving both sexes are needed.
In conclusion, COMT gene polymorphism contributes to the variable pharmacodynamic
responses to propranolol in patients with chronic musculoskeletal pain. COMT haplotypes may
serve as genetic predictors of treatment outcome and permit the identification of the subgroup
of patients who will benefit from propranolol therapy. The results of this study may also explain
the variability of treatment responses to β-blockers for a broad spectrum of diseases.
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Schematic diagram of COMT gene. Boxes depict exons. Locations of the SNPs selected for
the study are marked by arrows.
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Flow of the subjects through the study.
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Net changes in measures of the reported pain and experimental pain sensitivity categorized by
the number of LPS alleles of COMT. Subjects not carrying LPS allele show the best response
to propranolol therapy in all pain measures except thermal threshold. Data are expressed as
Means±SE. *p<0.05 different from LPS homozygotes, **p<0.01 different from LPS hetero-
and homozygotes with Tukey's post hoc test.
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Table 2
Frequency of COMT diplotypes (n=40)
Diplotype SNPs allele Number (%)
APS/HPS ATCA/ACCG 1 (2.5%)
APS/APS ATCA/ATCA 12 (30%)
LPS/APS GCGG/ATCA 19 (47.5%)
LPS/LPS GCGG/GCGG 8 (20%)
SNP, single nucleotide polymorphism













Tchivileva et al. Page 19
Table 3
Comparison of outcome changes in placebo and propranolol arm (n=40)
Outcome Placebo Mean (SD) Propranolol Mean (SD) P value
Clinical pain:
    Pain intensity (NRS 0-100) -0.1 (10.8) -4.6 (13.3) 0.104
    Pain duration (% of day) -3.5(18.1) -4.5(16.7) 0.802
    Pain index 34(862) -453(1167) 0.020
Experimental heat pain:
    Thermal Threshold (°C) 0.22 (1.26) 0.43 (1.16) 0.449
    Thermal Tolerance (°C) -0.02 (0.82) 0.26 (0.61) 0.081
Experimental pressure pain:
    M. temporalis PPT (kg) 0.10 (0.41) 0.11 (0.50) 0.944
    M. masseter PPT (kg) 0.16 (0.38) 0.04 (0.34) 0.214
    TMJ PPT (kg) 0.04 (0.41) 0.11 (0.52) 0.576
Psychological measures:
    BDI (range 0-63) -1.8 (3.5) -0.5 (2.9) 0.206
    STAI Y-1 (range 20-80) -1.1 (5.6) -0.8 (6.9) 0.689
    PSS (range 0-40) 0.1 (3.7) -1.4 (3.1) 0.087
CVS measures:
    SBP (mmHg) -1.8 (6.3) -4.3 (6.7) 0.131
    DBP (mmHg) -1.2 (6.2) -3.3 (5.2) 0.117
    HR (bpm) -0.1 (6.0) -7.1 (9.4) 0.001
PPT, pressure pain threshold; TMJ, temporomandibular joint; BDI, Beck depression inventory; STAI, state-trait anxiety inventory; PSS, perceived
stress scale; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate
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Table 4
Net changes in psychological and CVS measures (Mean (SE)) categorized by the number of LPS alleles of
COMT gene
Outcome 0 LPS (n=13) 1 LPS (n=19) 2 LPS (n=8) P value
Psychological measures:
    BDI 0.5 (1.4) 1.9 (1.3) 0.8 (1.2) 0.714
    STAI Y-1 -2.2 (2.5) 1.3 (2.4) 1.8 (1.5) 0.630
    PSS 1.2 (1.2) 2.7 (1.1) -0.9 (1.8) 0.342
CVS measures:
    SBP (mmHg) -4.4 (3.7) -2.6 (1.9) 0.8 (2.1) 0.499
    DBP (mmHg) -1.8 (3.3) -3.4 (1.6) 0.4 (4.7) 0.583
    HR (bpm) -9.9 (3.5) -9.7 (2.0) 3.3 (4.4) 0.017
BDI, Beck depression inventory; STAI, state-trait anxiety inventory; PSS, perceived stress scale; SBP, systolic blood pressure; DBP, diastolic blood
pressure; HR, heart rate
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